Ruxolitinib

Drug Profile

Ruxolitinib

Alternative Names: INC-424; INCB 018424 phosphate; INCB-018424; INCB-18424; Jakafi; Jakavi; ruxolitinib phosphate

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Developer Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute; Incyte Corporation; Lymphoma Academic Research Organisation; Novartis; RWTH Aachen University; Sunnybrook Health Sciences Centre; University Health Network of Toronto; University of Cologne; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Antineoplastics; Antipsoriatics; Antirheumatics; Cyclopentanes; Nitriles; Pyrazoles; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Polycythaemia vera; Myelofibrosis; Essential thrombocythaemia; Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myelofibrosis; Polycythaemia vera
  • Phase III Essential thrombocythaemia; Graft-versus-host disease
  • Phase II Acute lymphoblastic leukaemia; Alopecia areata; Atopic dermatitis; Breast cancer; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Hodgkin's disease; Myelodysplastic syndromes; Thalassaemia; Vitiligo
  • Phase I/II Acute myeloid leukaemia; Chronic myeloid leukaemia
  • No development reported Psoriasis
  • Discontinued Colorectal cancer; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Rheumatoid arthritis

Most Recent Events

  • 12 May 2017 Incyte initiates an expanded access for Graft versus host disease (In children, In adolescents, In adults) in USA (NCT03147742)
  • 01 May 2017 Novartis Pharmaceuticals terminates the phase III ReTHINK trial for Myelofibrosis due to unresolvable inability to recruit the patients in Austria, Belgium, Germany, Israel, Japan, Norway, Spain, Sweden, Switzerland, Hungary, Greece, France, Portugal, Finland, Denmark and Poland (PO) (NCT02598297)
  • 26 Apr 2017 Phase-II clinical trials in Breast cancer (Neoadjuvant therapy, Combination therapy, Metastatic disease) in USA (PO) (NCT02876302)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top